(Q47679260)

4 February 2018

title

177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment (English)

1 reference

4 February 2018

1 reference

1 reference

Madhav Prasad Yadav

1

1 reference

4 February 2018

Sanjana Ballal

2

1 reference

4 February 2018

Madhavi Tripathi

3

1 reference

4 February 2018

Nishikant Avinash Damle

4

1 reference

4 February 2018

Ranjit Kumar Sahoo

5

1 reference

4 February 2018

Amlesh Seth

6

1 reference

4 February 2018

Chandrasekhar Bal

7

1 reference

4 February 2018

publication date

10 August 2016

1 reference

4 February 2018

number of pages

11

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

4 February 2018

volume

44

1 reference

4 February 2018

issue

1

1 reference

4 February 2018

page(s)

81-91

1 reference

4 February 2018

https://scigraph.springernature.com/pub.10.1007/s00259-016-3481-7

exact match

0 references

cites work

Characterising the castration-resistant prostate cancer population: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Physical models and dose factors for use in internal dose assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Antibody-directed effector cell therapy of tumors: analysis and optimization using a physiologically based pharmacokinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-016-3481-7

Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.

21 January 2018

1 reference

12 December 2020

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors

1 reference

12 December 2020

Current management of castrate-resistant prostate cancer.

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020

10.1007/S00259-016-3481-7

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018